Crenolanib is a small molecule tyrosine kinase inhibitor with that is effective against PDGFR-α and presently in clinical trials for patients with gastrointestinal stromal tumors (GIST) in which PDGFRA activation mutations confer resistance to imatinab (47). Here, PDGFRA is linked to gastrointestinal stromal tumor.